Developer docs
API playgroundTry for free, no card

Search company profiles

Neopharma

Full company profile

uuid000if3f

Namestring
Neopharma
Websiteurl
neopharma.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Neopharma is a privately held pharmaceutical company founded in 2003, headquartered in Bristol, United States, with 5,001-10,000 employees. The company self-describes as a global pharmaceutical provider operating across more than ten therapeutic areas, with an explicit strategic emphasis on novel therapeutics rather than purely generic or commodity products.

The company's offering spans branded and novel pharmaceutical products distributed across multiple therapeutic categories and international markets. No specific product list, pipeline assets, manufacturing footprint details, technology platform, or proprietary R&D assets are disclosed in the available input data, which constrains a more granular technical description. The website content available for analysis was a loading/verification placeholder and yielded no product-, pipeline-, or technology-level information.

The business model is consistent with a diversified mid-to-large pharmaceutical manufacturer: revenue is generated through the sale of pharmaceutical products across multiple therapeutic areas to a mix of institutional buyers, wholesalers, and healthcare providers across global markets. No pricing model, customer segmentation, distribution channel, partnership, marketing, or revenue mechanics are disclosed in the input. The company remains private, with no funding rounds, ownership structure, or investor information available, limiting further inference about capitalization and shareholder composition.

Short descriptiontext

Neopharma is a privately held global pharmaceutical company founded in 2003, operating across more than ten therapeutic areas with a focus on novel therapeutics. It employs 5,001-10,000 staff and serves international pharmaceutical markets.

Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersAbu Dhabi, United Arab Emirates
HQ citystring
Abu Dhabi
HQ countrystring
United Arab Emirates
HQ regionstring
Middle East
Markets served

Serves global market

Keyword5 values
pharmaceutical manufacturing, generic drug production, novel therapeutics development, therapeutic area products, global pharmaceutical supply
Industry3 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Manufacturing
Cost components5 values
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Neopharma manufactures and supplies high-quality pharmaceutical products across more than ten therapeutic areas on a global basis. Its portfolio combines established products with a focus on novel therapeutics, indicating both commercial-scale manufacturing and an innovation-driven development pipeline serving healthcare markets worldwide.

Differentiator
Functional benefit
Problem solved
Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global pharmaceutical company producing generics, biosimilars, and proprietary formulations across multiple therapeutic areas. Comparable to Neopharma on a broad multi-area portfolio, novel/branded formulations focus, and global commercial footprint.

2Sun Pharmaceutical Industries
TypeBroad incumbent
Description

One of the largest specialty and generic pharmaceutical companies globally, with a broad portfolio spanning multiple therapeutic areas including dermatology, neurology, and oncology. Comparable to Neopharma on broad therapeutic coverage but larger scale and more established specialty franchises.

TypeDirect peer
Description

Indian global pharmaceutical company with branded and generics offerings concentrated in cardiovascular, CNS, and other chronic therapy areas. Comparable to Neopharma on multi-therapeutic branded-generic operations and global commercial scale.

TypeBroad incumbent
Description

Large Indian pharmaceutical company with a broad portfolio across multiple therapeutic categories and significant emerging-market presence. Comparable to Neopharma on multi-therapeutic area pharma footprint and scale of operations.

TypeDirect peer
Description

Indian-listed global pharmaceutical manufacturer focused on finished dosage forms across niche therapeutic areas with regulated-market distribution. Comparable to Neopharma on global pharma manufacturing and multi-therapeutic area branded-generic operations.

TypeDirect peer
Description

Indian-headquartered global pharmaceutical company manufacturing branded and generic medicines across multiple therapeutic areas including respiratory, cardiovascular, and CNS. Directly comparable to Neopharma on diversified multi-therapeutic portfolio and global distribution scale.

7Julphar (Gulf Pharmaceutical Industries)
TypeRegional player
Description

UAE-headquartered pharmaceutical manufacturer producing branded generics across multiple therapeutic areas for regional markets. Adjacent peer to Neopharma in Mid-East presence and multi-therapeutic branded generic manufacturing.

TypeDirect peer
Description

Global pharmaceutical company focused on branded generics, specialty, and innovation across dermatology, respiratory, and oncology. Comparable to Neopharma on a mid-sized, multi-therapeutic-area branded pharma profile with R&D emphasis.

TypeDirect peer
Description

Vertically integrated global pharmaceutical manufacturer offering APIs and finished dosage forms across multiple therapeutic categories including anti-infectives, cardiovascular, and CNS. Directly comparable to Neopharma on diversified branded and generic pharma manufacturing at global scale.

TypeDirect peer
Description

Indian global pharmaceutical company with branded and generic offerings across cardiovascular, diabetology, respiratory, and other therapeutic areas. Peer to Neopharma in multi-therapeutic branded-generic pharma with global distribution.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neopharma

Pharmaceutical Manufacturingneopharma.com

Neopharma is a privately held global pharmaceutical company founded in 2003, operating across more than ten therapeutic areas with a focus on novel therapeutics. It employs 5,001-10,000 staff and serves international pharmaceutical markets.

What Neopharma does

Neopharma is a privately held pharmaceutical company founded in 2003, headquartered in Bristol, United States, with 5,001-10,000 employees. The company self-describes as a global pharmaceutical provider operating across more than ten therapeutic areas, with an explicit strategic emphasis on novel therapeutics rather than purely generic or commodity products.

The company's offering spans branded and novel pharmaceutical products distributed across multiple therapeutic categories and international markets. No specific product list, pipeline assets, manufacturing footprint details, technology platform, or proprietary R&D assets are disclosed in the available input data, which constrains a more granular technical description. The website content available for analysis was a loading/verification placeholder and yielded no product-, pipeline-, or technology-level information.

The business model is consistent with a diversified mid-to-large pharmaceutical manufacturer: revenue is generated through the sale of pharmaceutical products across multiple therapeutic areas to a mix of institutional buyers, wholesalers, and healthcare providers across global markets. No pricing model, customer segmentation, distribution channel, partnership, marketing, or revenue mechanics are disclosed in the input. The company remains private, with no funding rounds, ownership structure, or investor information available, limiting further inference about capitalization and shareholder composition.

Neopharma firmographics

Firmographics
Name
Neopharma
Website
https://neopharma.com
Company type
Private
Founded year
2003
Headcount range
251–500 employees
Short description
Neopharma is a privately held global pharmaceutical company founded in 2003, operating across more than ten therapeutic areas with a focus on novel therapeutics. It employs 5,001-10,000 staff and serves international pharmaceutical markets.
Ownership category
akta.pro rank

Neopharma industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)

Keywords

  • Pharmaceutical manufacturing
  • Generic drug production
  • Novel therapeutics development
  • Therapeutic area products
  • Global pharmaceutical supply

Where Neopharma is headquartered

Location

Headquarters

HQ city
Abu Dhabi
HQ country
United Arab Emirates
HQ region
Middle East

Markets served

Neopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Neopharma product offering

Product offering

Core offering

Neopharma manufactures and supplies high-quality pharmaceutical products across more than ten therapeutic areas on a global basis. Its portfolio combines established products with a focus on novel therapeutics, indicating both commercial-scale manufacturing and an innovation-driven development pipeline serving healthcare markets worldwide.

Differentiator

Problem solved

Functional benefit

Companies that use Neopharma

Customer profile

Ideal customer profiles1 record

Neopharma technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Neopharma partnerships and signals

Strategic signal

Expansion highlights2 records

Neopharma competitors and assessment

Company assessment

Direct peers

  • Dr. Reddy's Laboratories: Global pharmaceutical company producing generics, biosimilars, and proprietary formulations across multiple therapeutic areas. Comparable to Neopharma on a broad multi-area portfolio, novel/branded formulations focus, and global commercial footprint.
  • Torrent Pharmaceuticals: Indian global pharmaceutical company with branded and generics offerings concentrated in cardiovascular, CNS, and other chronic therapy areas. Comparable to Neopharma on multi-therapeutic branded-generic operations and global commercial scale.
  • Strides Pharma Science: Indian-listed global pharmaceutical manufacturer focused on finished dosage forms across niche therapeutic areas with regulated-market distribution. Comparable to Neopharma on global pharma manufacturing and multi-therapeutic area branded-generic operations.
  • Cipla: Indian-headquartered global pharmaceutical company manufacturing branded and generic medicines across multiple therapeutic areas including respiratory, cardiovascular, and CNS. Directly comparable to Neopharma on diversified multi-therapeutic portfolio and global distribution scale.
  • Glenmark Pharmaceuticals: Global pharmaceutical company focused on branded generics, specialty, and innovation across dermatology, respiratory, and oncology. Comparable to Neopharma on a mid-sized, multi-therapeutic-area branded pharma profile with R&D emphasis.
  • Aurobindo Pharma: Vertically integrated global pharmaceutical manufacturer offering APIs and finished dosage forms across multiple therapeutic categories including anti-infectives, cardiovascular, and CNS. Directly comparable to Neopharma on diversified branded and generic pharma manufacturing at global scale.
  • Lupin Limited: Indian global pharmaceutical company with branded and generic offerings across cardiovascular, diabetology, respiratory, and other therapeutic areas. Peer to Neopharma in multi-therapeutic branded-generic pharma with global distribution.

Broad incumbents

  • Sun Pharmaceutical Industries: One of the largest specialty and generic pharmaceutical companies globally, with a broad portfolio spanning multiple therapeutic areas including dermatology, neurology, and oncology. Comparable to Neopharma on broad therapeutic coverage but larger scale and more established specialty franchises.
  • Mankind Pharma: Large Indian pharmaceutical company with a broad portfolio across multiple therapeutic categories and significant emerging-market presence. Comparable to Neopharma on multi-therapeutic area pharma footprint and scale of operations.

Regional players

  • Julphar (Gulf Pharmaceutical Industries): UAE-headquartered pharmaceutical manufacturer producing branded generics across multiple therapeutic areas for regional markets. Adjacent peer to Neopharma in Mid-East presence and multi-therapeutic branded generic manufacturing.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Neopharma social profiles

Digital presence

Neopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neopharma leadership team

Management profile

Number of profiles

Neopharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neopharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neopharma

What does Neopharma do?

Neopharma manufactures and supplies high-quality pharmaceutical products across more than ten therapeutic areas on a global basis. Its portfolio combines established products with a focus on novel therapeutics, indicating both commercial-scale manufacturing and an innovation-driven development pipeline serving healthcare markets worldwide.

When was Neopharma founded?

Neopharma was founded in 2003. It employs 251 to 500 people.

Where is Neopharma based?

Neopharma is headquartered in Abu Dhabi, United Arab Emirates, in the Middle East region.

Who are Neopharma's main competitors?

Direct peers on record are Dr. Reddy's Laboratories, Torrent Pharmaceuticals, Strides Pharma Science, Cipla, Glenmark Pharmaceuticals, Aurobindo Pharma and Lupin Limited. Broad incumbents are Sun Pharmaceutical Industries and Mankind Pharma. Julphar (Gulf Pharmaceutical Industries) is listed as a regional player.

Does Neopharma have an API?

No public API is recorded for Neopharma.

What industry is Neopharma in?

Neopharma's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TrendTurkmenistan, UAE's Neopharma discuss pharmaceutical cooperationTurkmenistan and UAE-based Neopharma LLC discussed pharmaceutical cooperation in Abu Dhabi, including medicine supplies, technology transfer, and production capacity. The sides agreed to continue dialogue through Turkmenistan's Ministry of Health and Medical Industry. Neopharma operates 10 facilities and supplies medicines to over 50 markets.PR NewswireUAE Contract Manufacturing Organizations Market Report 2023: Emergence of CMOs with Growing Production Capacities Promotes the Market Growth - Competition, Forecasts & Opportunities to 2027ResearchAndMarkets.com published a market report projecting robust growth for the UAE Contract Manufacturing Organizations (CMO) market during 2023-2027, driven by increasing demand for pharmaceutical outsourcing and biologics manufacturing. The market growth is attributed to the rising need for cost-effective manufacturing services, the entry of novel CMOs with advanced capabilities, and escalating chronic disease prevalence. Key market players profiled include Life Pharma FZE, Pharmax Pharmaceuticals FZ-LLC, Julphar Pharmaceuticals, Vieco Pharmaceuticals FZCO, ADCAN Pharma, and Neopharma Pharmaceuticals.Arabian BusinessLenders to BR Shetty’s pharma firm are said to start debt talksLenders to Neopharma, a pharma firm founded by Bavaguthu Raghuram Shetty, will meet Thursday to restructure 1 billion dirhams ($272 million) of debt. Creditors may also bring in a strategic investor to keep the business operating. Neopharma is linked to NMC Health, which is in administration after fraud allegations.FiercePharmaNeopharma snatches Dr. Reddy's API plant as it continues global expansionDr. Reddy's Laboratories has sold its API manufacturing plant in Hyderabad to Therapiva, a joint venture between Abu Dhabi-based Neopharma and India's Laxai Life Sciences, as part of cost-streamlining efforts. The transaction includes manufacturing plants, current assets and liabilities, and employees, but excludes two API plants currently under FDA warning letters. This follows Dr. Reddy's recent sale of its U.S. antibiotics plant in Bristol, Tennessee to Neopharma, as the Indian drugmaker continues to address years of financial struggles tied to regulatory issues.RediffDr Reddy's sells US facility to UAE-based NeopharmaDr. Reddy's Laboratories has sold its antibiotics manufacturing facility in Bristol, Tennessee, to UAE-based Neopharma, completing the transaction seven years after acquiring the site from GlaxoSmithKline in 2011. The 390,000 sq ft facility, dedicated to secondary oral-solid dose penicillin manufacturing including Amoxicillin-based products, was sold as part of Dr. Reddy's strategy to streamline global cost structures and refocus on complex generic products amid commoditization of oral penicillin in the US. Dr. Reddy's also terminated a license agreement with Armis Biopharma and regained worldwide rights to investigational antibacterial product DFA-02.DaijiworldFoundation laid for B R Shetty's $1.8-bn BRS Medicity near AmaravatiAndhra Pradesh Chief Minister N. Chandrababu Naidu laid the foundation stone for BRS Medicity, a $1.8 billion healthcare project by Dr. B R Shetty's group near Amaravati. The facility will feature a 1,500-bed hospital and partner with the University of California, San Diego to provide medical education and research opportunities. Neopharma is also set to build a manufacturing facility in Amaravati to support the hospital's equipment needs.PR NewswireCountryFocus: Healthcare, Regulatory and Reimbursement Landscape - United Arab EmiratesA 2016 market research report describes the UAE pharmaceutical market as the second-largest in the GCC, valued at $3.05 billion in 2015 and projected to reach $5.71 billion by 2020, growing at a CAGR of 13.4%. The report profiles key pharmaceutical companies including Julphar, Neopharma, Pfizer, GlaxoSmithKline, and Novartis, and examines the regulatory and reimbursement landscape. It identifies medical tourism, expanding health insurance, and increasing healthcare expenditure as primary growth drivers for the UAE healthcare sector.